Belite Bio, Inc (BLTE): Capital Expenditures
$71.0K
Year ended 2025-12-31
-43.5%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.0K | -38.8% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $116.0K | +84.1% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $63.0K | -84.0% | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | $394.0K | +432.4% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $74.0K | n/a | 2024-03-12, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Belite Bio, Inc (BLTE) | 2025-12-31 | $71.0K | -38.8% |
| Spyre Therapeutics, Inc. (SYRE) | 2024-12-31 | $0 | n/a |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $13.15M | -55.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
| MannKind Corp (MNKD) | 2025-12-31 | $4.57M | -52.9% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $16.44M | -4.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.57M | +466.1% |
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $933.0K | +84.8% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $12.01M | +832.5% |
Compare BLTE, SYRE, MRVI, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗